Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mutual Alleges Mucinex Monopoly In Extended-Release Guaifenesin

This article was originally published in The Tan Sheet

Executive Summary

Mutual Pharmaceutical alleges in an antitrust suit that RB attempts to monopolize the extended-release guaifenesin OTC category with its Mucinex product. The suit says Mutual has lost “tens of millions” due to RB's failure to honor a contract to supply an “authorized generic” of the product.

You may also be interested in...



Reckitt Negotiating Details For Generic Mucinex It Will Provide Mutual

Litigation over supply agreement stayed after firms indicated to US district court they would settle. Mutual showed that RB failed to honor an agreement to supply generics of the original Mucinex guaifenesin, but had not provided sufficient detail for RB to provide a product that would meet regulatory standards.

Reckitt Negotiating Details For Generic Mucinex It Will Provide Mutual

Litigation over supply agreement stayed after firms indicated to US district court they would settle. Mutual showed that RB failed to honor an agreement to supply generics of the original Mucinex guaifenesin, but had not provided sufficient detail for RB to provide a product that would meet regulatory standards.

Congestion Continues In Private Label Mucinex Pipeline; Court Rules Against Mutual

A ruling for RB n Pennsylvania federal court comes as it girds for increased competition from additional guaifenesin expectorant formulations that are the equivalents of Mucinex brand products and that Perrigo is marketing under license from manufacturer Allergan.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS107544

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel